Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629060 | 0.94 | KEAP1 (1.00) | KEAP1NFE2L2 | |
| SCHEMBL1629905 | 0.89 | KEAP1 (0.76) | KEAP1NFE2L2 | |
| SCHEMBL1631020 | 0.88 | KEAP1 (0.87) | KEAP1NFE2L2 | |
| SCHEMBL1630949 | 0.88 | KEAP1 (0.87) | KEAP1NFE2L2 | |
| SCHEMBL7109099 | 0.87 | BMP1 (0.74) | KEAP1NFE2L2 | |
| SCHEMBL1629157 | 0.86 | KEAP1 (0.70) | KEAP1NFE2L2 | |
| SCHEMBL1631682 | 0.86 | KEAP1 (0.70) | KEAP1NFE2L2 | |
| SCHEMBL7000752 | 0.85 | KEAP1 (0.66) | KEAP1NFE2L2 | |
| SCHEMBL20723407 | 0.85 | KEAP1 (1.00) | KEAP1NFE2L2 | |
| SCHEMBL1629150 | 0.85 | KEAP1 (0.77) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | HO WEN-BIN (US) | 2003-10-09 | — | — | US | disclosed |
| EP-1154992-A4 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN INC (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6506936-B1 | Treating fibrotic disorder selected from hepatic cirrhosis and arthritis; inhibiting matrix metalloproteases | FIBROGEN, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1154992-A1 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN, INC. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050390-A1 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | MMP1, MMP13, COL14A1 | KEAP1 880/4885NFE2L2 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.